Skip to search formSkip to main contentSkip to account menu

KRAS NP_004976.2:p.G13X

Known as: GTPase KRas G13X, KRAS G13 Mutation, KRAS p.Gly13Xxx 
A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by another amino acid.
National Institutes of Health

Related topics

Related topics

1 relation
Kras gene mutation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers
ObjectivesTo evaluate the benefit of cetuximab (Cx) addition to platinum-based and 5-fluorouracil chemotherapy (PFU) in… 
Review
2017
Review
2017
Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90
PurposeTo determine whether pathologic colorectal tumor KRAS mutation status is correlated with progression-free survival (PFS… 
2012
2012
KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
Background:Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are restricted to KRAS wild-type (WT) metastatic… 
2012
2012
Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma
Mutations in the v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) are present in approximately 30% to 40% of… 
2011
2011
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.
OBJECTIVE Mutation status of the KRAS gene in tumors has been shown to be a predictive biomarker of response to anti-epidermal… 
2010
2010
Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation.
AIM To compare the differences between dideoxy sequencing/KRAS StripAssay/pyrosequencing for detection of KRAS mutation in… 
2009
2009
[Validation study of KRAS mutation in colorectal cancer].
There is no doubt that molecular targeted therapy has increasing importance in clinical oncology. Markers related to the… 
2009
2009
DUSPs as markers of MEK/Erk activation in primary colorectal cancer.
4064 Background: DUSPs dephosphorylate P-MAPK and are activated as a negative feedback loop upon RTK signaling. Higher expression… 
2009
2009
Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG…
4055 Background: Previous retrospective analyses of KRAS mutation status from the randomized CECOG/CORE 1.2.001 phase II trial… 
1998
1998
Molekulargenetik der epithelialen Ovarialneoplasien: Korrelationen zum Phänotyp und biologischen Verhalten
ZusammenfassungDie phänotypischen Unterschiede zwischen den verschiedenen Formen der epithelialen Ovarialneoplasien haben… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)